Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Innoviva Inc    INVA

INNOVIVA INC (INVA)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/17/2018 01/18/2018 01/19/2018 01/22/2018 01/23/2018 Date
14.52(c) 14.37(c) 14.83(c) 15.25(c) 15.68 Last
563 435 241 725 619 718 1 478 765 1 290 385 Volume
-0.27% -1.03% +3.20% +2.83% +2.82% Change
More quotes
Financials ($)
Sales 2017 219 M
EBIT 2017 183 M
Net income 2017 139 M
Debt 2017 492 M
Yield 2017 1,64%
Sales 2018 288 M
EBIT 2018 261 M
Net income 2018 251 M
Debt 2018 270 M
Yield 2018 1,64%
P/E ratio 2017 14,22
P/E ratio 2018 7,10
EV / Sales2017 9,79x
EV / Sales2018 6,65x
Capitalization 1 647 M
More Financials
Company
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals.Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone... 
Sector
Pharmaceuticals
Calendar
02/08Earnings Release
More about the company
Surperformance© ratings of Innoviva Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on INNOVIVA INC
01/11 INNOVIVA,INC. (NASDAQ : INVA) Files An 8-K Amendments to Articles of Incorporati..
01/10 INNOVIVA, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
2017 INNOVIVA,INC. (NASDAQ : INVA) Files An 8-K Regulation FD Disclosure
2017 INNOVIVA, INC. : Regulation FD Disclosure (form 8-K)
2017 INNOVIVA,INC. (NASDAQ : INVA) Files An 8-K Departure of Directors or Certain Off..
2017 INNOVIVA, INC. : Change in Directors or Principal Officers, Regulation FD Disclo..
2017 INNOVIVA : and Sarissa Implement Court Order
2017 INNOVIVA,INC. (NASDAQ : INVA) Files An 8-K Regulation FD Disclosure
2017 INNOVIVA, INC. : Regulation FD Disclosure (form 8-K)
2017 GLAXOSMITHKLINE : GSK Submits Landmark IMPACT Data to US Regulatory Authority to..
More news
Sector news : Pharmaceuticals - NEC
08:48a Drug Firms Bet Billions on Biotech -- WSJ
01/22 WILLIAM ACKMAN : Ackman cuts staff, shuns limelight as he seeks to turn around f..
01/22 TSX dips as railroad and materials shares weigh
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Canada's small financial firms get buzz from weed stocks
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/22Innoviva, Glaxo Partnership Has Been A Lucrative One So Far
1
01/20California State Teachers Retirement System Has $1.71 Million Holdings in Inn.. 
01/10$THRX New SEC Document(s) for Innoviva, Inc. From our Stock News Alerts App 
01/08Want the latest upgrades & downgrades for $TYL $ARW $QRVO $INVA $RDN? Che.. 
01/05TREND REVERSAL DOWN ALERT: $INVA INNOVIVA ? TradeIdeas via  
More tweets
Qtime:43
News from SeekingAlpha
01/20 STOCKS TO WATCH : Earnings Season Hits Higher Gear
01/03 Beating The Market With A Simple Quantitative System
2017 Premarket analyst action - healthcare
2017 Innoviva (INVA) Presents At Stifel 2017 Healthcare Conference - Slideshow
2017 Glaxo's inhaled triplet therapy for COPD OK'd in Europe
Chart INNOVIVA INC
Duration : Period :
Innoviva Inc Technical Analysis Chart | INVA | US45781M1018 | 4-Traders
Technical analysis trends INNOVIVA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 12,8 $
Spread / Average Target -16%
EPS Revisions
Managers
NameTitle
Michael W. Aguiar President, Chief Executive Officer & Director
William H. Waltrip Chairman
Eric d'Esparbes Chief Financial Officer & Senior Vice President
Theodore J. Witek Chief Scientific Officer & Senior Vice President
Catherine J. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INNOVIVA INC4.51%1 647
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132